AB201. Two birds with one stone: α-blocker therapy on LUTS/BPH in men concomitant with mild hypertension

OBJECTIVE: To assess the clinical efficacy and safety of administering doxazosin as an alpha 1-blocker in patients with comorbid LUTS/BPH and mild hypertension. METHODS: One hundred and fifty-six enrolled men concomitant with comorbid LUTS/BPH and mild hypertension who completed the International Prostate Symptom Score (IPSS >7 points) at the first visit in our clinic were eligible in this trial. All the patients were assessed based on IPSS, IPSS-Quality of Life for LUTS/BPH and received blood pressure (BP) determination. Those men with normotensive and moderate-to-severe hypertension were excluded. Urologic and cardiologic assessment included uroflowmetry (maximum urinary flow rate, Qmax), IPSS, and BP measurements. They were administered with 4 mg of doxazosin once daily for 12 weeks. Changes of IPSS, Qmax, Quality of Life for LUTS/BPH, systolic and diastolic BP were evaluated every 4 weeks. Safety was mainly assessed via spontaneous reports of adverse events. RESULTS: After treatment with doxazosin, IPSS in those LUTS/BPH men significantly decreased (15.2±4.8 vs. 10.7±3.5 points, P<0.001), whereas Qmax increased (9.4±2.5 and 11.8±4.3 mL/s, P<0.01), respectively. Doxazosin demonstrated efficacy in lowering IPSS score and relieving LUTS. Of them, systolic and diastolic BP of 124 patients (79.5%) decreased to normal. Most patients were generally well tolerant to the treatment and there was no evidence of additional side effects related to administration. No orthostatic hypotension and other BP-related adverse profiles occurred in all patients. CONCLUSIONS: Our data show that doxazosin as an alpha 1-blocker treatment appears to be efficacious in both relieving bothersome lower urinary tract symptoms and decreasing BP in LUTS/BPH men with mild hypertension.